Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
22 January 2019
Just published is a new OHE Consulting Report that explores society’s preferences across curative and non-curative therapies and large and small health gains.
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel,…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA,…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by…
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
1 February 2019
Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available…
A Note on the Relationship Between Age and Health-related Quality of Life Assessment
12 December 2018
A new OHE-authored paper on the relationship between age and health-related quality of life has been published in Quality of Life Research.
New Publications: Real-World Evidence for Coverage and Formulary Decisions
7 December 2018
Two articles, published in the Journal of Comparative Effectiveness Research, explore the use of real-world evidence for coverage and formulary decisions.
Presentations from ISPOR Europe 2018
23 November 2018
OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations.
OHE at ISPOR Europe 2018
7 November 2018
Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 conference in Barcelona, 10-14 November.